NIVOLUMAB(N)‐AVD IMPROVES PROGRESSION‐FREE SURVIVAL COMPARED TO BRENTUXIMAB VEDOTIN(BV)‐AVD IN ADVANCED STAGE (AS) CLASSIC HODGKIN LYMPHOMA (HL): RESULTS OF SWOG S1826

Overview of attention for article published in Hematological Oncology, June 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#29 of 1,608)
High Attention Score compared to outputs of the same age (91st percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news: 2 news outlets
twitter: 16 X users

reddit: 1 Redditor

Readers on

mendeley: 6 Mendeley

So far, Altmetric has seen 16 X posts from 16 X users, with an upper bound of 26,212 followers.

Now this is the kind of study needed, specially when BV is so expensive n almost non affordable for patients n Nivo is somewhat manageable…Coz when u practice, pocket of patients decides treatment. Waiting for long term data n more such studies..#HodgkinL…

RT @smbenlazar: NIVOLUMAB‐AVD IMPROVES PROGRESSION‐FREE SURVIVAL COMPARED TO BRENTUXIMAB VEDOTIN‐AVD IN ADVANCED STAGE CLASSIC HODGKIN LYM…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 12 additional X posts.